A Study to Evaluate of the Absorption, Metabolism, and Excretion of 14C-JNJ-39823277 in Healthy Male Participants

NCT02049697 ↗

Phase 1 Completed 6 enrolled Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to investigate the absorption, metabolic pathways and excretion of JNJ-39823277 in healthy male adults after administration of a single oral dose of a 25 mg (0.5 mg/mL solution) of 14C-JNJ-39823277.

Timeline

Start: 2009-04
Primary completion: 2009-05
Completion: 2009-05

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Tianeptine	Small molecule	25 mg	Oral

Indications

No indication recorded.